Clinical Trial Update: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Update on the completed Phase 1/2 study of ZX-101A assessing activity, safety, and tolerability in relapsed/refractory hematological malignancies, including non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• ZX-101A

Snippet

Sponsor: Nanjing Zenshine Pharmaceuticals | Conditions: Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED